Chroma/CTI plan tosedostat PhIII to avoid AML trap that caught Vion, J&J and Genzyme
This article was originally published in Scrip
Executive Summary
The mood of de-risking that prevails in the life sciences at the moment means that the transition of its lead compound tosedostat from Phase II studies to two Phase III registrational trials for acute myeloid leukaemia (AML) in 2012 is a crucial step for Chroma Therapeutics, the UK-based originator of the molecule and for Cell Therapeutics Inc., Chroma's US-based licensee for the Americas (North, South and Central).